Midday Report: T2 Biosystems (TTOO) Shares Climb for August 4

Equities Staff  |

T2 Biosystems Inc (NASDAQ: TTOO) has risen $0.007 (5.80%) and is currently sitting at $0.12, as of 12:09:50 est on August 4.

10,426,919 shares have been traded today.

The Company has fallen 10.12% over the last 5 days and shares have fallen 28.94% over the last 30 days.

T2 Biosystems is set to release earnings on 2022-08-15.

For technical charts, analysis, and more on T2 Biosystems visit the company profile.

About T2 Biosystems Inc

T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems' products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, the T2Resistance™ Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Cauris™ Panel, and T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens.

To get more information on T2 Biosystems Inc and to follow the company's latest updates, you can visit the company's profile page here: T2 Biosystems Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

testforhref
The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation



Market Movers

Sponsored Financial Content